Fig. 3From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapyKaplan-Meier disease-free (a, c, e, g) and overall survival (b, d, f, h) curves among patients with tamoxifen monotherapy. Bold lines, Bcl-2-positive; thin lines, Bcl-2-negative. Total patients (a, b), patients with ER-positive and/or PR-positive tumors (c, d), patients with ER-negative and PR-negative tumors (e, f), and patients with triple-negative tumors (g, h). The P-value was determined by the log-rank test. *Significant, P <0.05Back to article page